Biorce Secures $52.5M, Propels AI Clinical Trial Revolution
February 3, 2026, 3:35 am
Biorce, a Barcelona-based AI health leader, closed a landmark $52.5M Series A funding. This capital fuels global expansion and product development. Its Aika platform revolutionizes clinical trials. Aika leverages AI to optimize trial design, anticipate risks, and drastically reduce costly protocol amendments. This accelerates new therapy development by up to 50%. Total company funding now surpasses $60M. Key investors include DST Global Partners, Norrsken VC, and YZR Capital. Biorce targets the $120B global clinical trial management market. It plans a strategic US expansion, launching a new R&D hub in Austin, Texas. This move strengthens its position, enhancing patient access to vital treatments and setting a new industry standard for clinical research efficiency.
AI Transforms Clinical Trials
A new era in drug development is here. Biorce, a Barcelona-based health AI company, is leading this change. The firm just closed a significant $52.5 million Series A funding round. This massive investment propels its mission. It will transform how clinical trials operate globally. Biorce’s total funding now exceeds $60 million. This marks a pivotal moment for health technology. It also represents the largest Series A in the Iberian healthtech and AI ecosystem to date.
Clinical trials traditionally face immense hurdles. Protocol amendments often halt patient recruitment. These pauses average six weeks. They add between $500,000 and $1 million in costs per amendment. This amounts to billions annually across the industry. Regulatory agencies like the FDA and EMA often demand clearer justification for trial designs. This triggers reviews, delays, and further amendments. New treatments reach patients too slowly. Lives hang in the balance. The system needs radical improvement.
Biorce offers a powerful solution. Its Aika platform is AI-native. Aika is built on approximately one million clinical trials data. It anticipates risks. It reduces errors. It virtually eliminates costly protocol amendments. The platform accelerates new therapy development. It can cut timelines by up to 50%. Aika helps pharmaceutical companies, biotech firms, and contract research organizations (CROs) design better trials. It maintains scientific standards. It ensures patient safety.
Aika’s design is therapy-agnostic. It applies across diverse therapeutic areas. Oncology, neurology, and rare diseases are all covered. This broad applicability allows Biorce to scale its AI impact. It sets a new industry standard for clinical trial design and management. The platform supports protocol design, feasibility analysis, and regulatory planning. All functions integrate into a single workspace. It reduces complexity for clinical teams. It cuts costs. It shortens development timelines.
The recent funding round saw strong participation. DST Global Partners made a new investment. Existing investors Norrsken VC and YZR Capital increased their stakes. Mustard Seed Maze also participated. Endeavor Catalyst joined the round. Prominent angel investors backed Biorce. These include Nik Storonsky of Revolut and Arthur Mensch of Mistral AI. Paulo Rosado of OutSystems, Albert Nieto of Seedtag, and Stef Van Grieken of Cradle also invested. This demonstrates robust market confidence.
Biorce’s growth has been exponential. The company previously secured €8.5 million in seed investment. This included €3.5 million in November 2024. A €5 million extension followed in summer 2025. The speed of these rounds confirms strong investor belief. They trust Biorce’s technology. They trust its execution. They believe in its long-term vision. Biorce ended last year exceeding its revenue target by 200%.
Global expansion is a core objective. Biorce plans to grow its team. It targets 250 employees by late 2026. A major development and R&D hub will open in Austin, Texas. This move strengthens Biorce’s US presence. It positions the company near leading pharmaceutical, biotech, and innovation ecosystems. Austin offers a strategic advantage. It connects Biorce directly to a crucial market. The global clinical trials management market is vast. It represents an estimated $120 billion in annual spending. Biorce aims to define its future.
A clear roadmap is set for 2026 and beyond. Biorce will strengthen Aika’s protocol intelligence capabilities. New modules are planned. These include contract management and negotiation tools. Budget planning and operational execution tools will follow. These additions simplify trial execution. They improve patient access to innovative therapies. This comprehensive approach underscores Biorce’s commitment to innovation. It promises a more efficient, patient-centric future.
Spain’s tech scene is vibrant. Biorce stands out among its rising stars. Barcelona and Madrid are key innovation hubs. The country offers an expanding investor base. It boasts a strong talent pool. International ambition fuels its growth. Biorce exemplifies this dynamic ecosystem. It leads the charge in healthtech AI. Its success reflects Spain's broader digital transformation.
Biorce is building essential AI infrastructure. This defines a new industry standard. Clinical trials will become faster. They will be more reliable. They will be more accessible. Patients will benefit sooner from new treatments. This investment is not just financial. It is a vote of confidence in a healthier future. Biorce is poised to lead this transformation. Its impact will resonate worldwide. It will reshape health outcomes for millions.
AI Transforms Clinical Trials
A new era in drug development is here. Biorce, a Barcelona-based health AI company, is leading this change. The firm just closed a significant $52.5 million Series A funding round. This massive investment propels its mission. It will transform how clinical trials operate globally. Biorce’s total funding now exceeds $60 million. This marks a pivotal moment for health technology. It also represents the largest Series A in the Iberian healthtech and AI ecosystem to date.
Clinical trials traditionally face immense hurdles. Protocol amendments often halt patient recruitment. These pauses average six weeks. They add between $500,000 and $1 million in costs per amendment. This amounts to billions annually across the industry. Regulatory agencies like the FDA and EMA often demand clearer justification for trial designs. This triggers reviews, delays, and further amendments. New treatments reach patients too slowly. Lives hang in the balance. The system needs radical improvement.
Biorce offers a powerful solution. Its Aika platform is AI-native. Aika is built on approximately one million clinical trials data. It anticipates risks. It reduces errors. It virtually eliminates costly protocol amendments. The platform accelerates new therapy development. It can cut timelines by up to 50%. Aika helps pharmaceutical companies, biotech firms, and contract research organizations (CROs) design better trials. It maintains scientific standards. It ensures patient safety.
Aika’s design is therapy-agnostic. It applies across diverse therapeutic areas. Oncology, neurology, and rare diseases are all covered. This broad applicability allows Biorce to scale its AI impact. It sets a new industry standard for clinical trial design and management. The platform supports protocol design, feasibility analysis, and regulatory planning. All functions integrate into a single workspace. It reduces complexity for clinical teams. It cuts costs. It shortens development timelines.
The recent funding round saw strong participation. DST Global Partners made a new investment. Existing investors Norrsken VC and YZR Capital increased their stakes. Mustard Seed Maze also participated. Endeavor Catalyst joined the round. Prominent angel investors backed Biorce. These include Nik Storonsky of Revolut and Arthur Mensch of Mistral AI. Paulo Rosado of OutSystems, Albert Nieto of Seedtag, and Stef Van Grieken of Cradle also invested. This demonstrates robust market confidence.
Biorce’s growth has been exponential. The company previously secured €8.5 million in seed investment. This included €3.5 million in November 2024. A €5 million extension followed in summer 2025. The speed of these rounds confirms strong investor belief. They trust Biorce’s technology. They trust its execution. They believe in its long-term vision. Biorce ended last year exceeding its revenue target by 200%.
Global expansion is a core objective. Biorce plans to grow its team. It targets 250 employees by late 2026. A major development and R&D hub will open in Austin, Texas. This move strengthens Biorce’s US presence. It positions the company near leading pharmaceutical, biotech, and innovation ecosystems. Austin offers a strategic advantage. It connects Biorce directly to a crucial market. The global clinical trials management market is vast. It represents an estimated $120 billion in annual spending. Biorce aims to define its future.
A clear roadmap is set for 2026 and beyond. Biorce will strengthen Aika’s protocol intelligence capabilities. New modules are planned. These include contract management and negotiation tools. Budget planning and operational execution tools will follow. These additions simplify trial execution. They improve patient access to innovative therapies. This comprehensive approach underscores Biorce’s commitment to innovation. It promises a more efficient, patient-centric future.
Spain’s tech scene is vibrant. Biorce stands out among its rising stars. Barcelona and Madrid are key innovation hubs. The country offers an expanding investor base. It boasts a strong talent pool. International ambition fuels its growth. Biorce exemplifies this dynamic ecosystem. It leads the charge in healthtech AI. Its success reflects Spain's broader digital transformation.
Biorce is building essential AI infrastructure. This defines a new industry standard. Clinical trials will become faster. They will be more reliable. They will be more accessible. Patients will benefit sooner from new treatments. This investment is not just financial. It is a vote of confidence in a healthier future. Biorce is poised to lead this transformation. Its impact will resonate worldwide. It will reshape health outcomes for millions.